| Segment Reporting |
Note
7 – Segment Reporting
We
manage our operations as a 1 single segment, focused on developing the next generation of cancer therapy drugs. As our chief
operating decision maker (CODM), our CEO manages and allocates resources at a consolidated level. He assesses performance, monitors
budget versus actual results, and decides how to allocate resources based on net loss that also is reported on the consolidated
statement of operations and comprehensive loss as consolidated net loss.
The
following table presents reportable segment profit and loss, including significant expense categories, attributable to our reportable
segment for the three months ended March 31, 2026 and 2025:
Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories
| |
|
2025 |
|
|
2025 |
|
| |
|
Three months ended March 31, |
|
| |
|
2026 |
|
|
2025 |
|
| Preclinical, clinical trial and other costs |
|
$ |
1,423,041 |
|
|
$ |
1,197,035 |
|
| Research and development personnel expense(1) |
|
|
386,168 |
|
|
|
391,505 |
|
| General and administrative personnel expense(2) |
|
|
676,382 |
|
|
|
673,779 |
|
| Administrative and facilities expense(3) |
|
|
845,623 |
|
|
|
584,671 |
|
| Other income, net(4) |
|
|
45,965 |
|
|
|
(12,585 |
) |
| Total |
|
$ |
3,377,179 |
|
|
$ |
2,834,405 |
|
| Net loss |
|
$ |
3,377,179 |
|
|
$ |
2,834,405 |
|
| (1) |
|
Research
and development personnel costs include employee stock-based compensation expense of $17,144 and $46,720 for the three months ended
March 31, 2026 and 2025, respectively. |
| (2) |
|
General
and administrative personnel costs include employee stock-based compensation expense of $52,387 and $122,655 for the three months
ended March 31, 2026 and 2025, respectively, and are net of reimbursements received from CorLyst, LLC. |
| (3) |
|
Administrative
& facilities expense primarily consists of facilities expenses, office expenses, legal costs, insurance, consulting, travel,
and other administrative costs. |
| (4) |
|
Other
income, net consists of interest and dividend income, unrealized loss on our digital asset, and other miscellaneous income. |
|